PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

  • STATUS
    Recruiting
  • End date
    Dec 31, 2025
  • participants needed
    116
  • sponsor
    Tanta University
Send
Updated on 8 May 2025
See if I qualify

Summary

The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients.

Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT.

Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).

Details
Condition Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
Age 18years or above
Clinical Study IdentifierNCT06960954
SponsorTanta University
Last Modified on8 May 2025

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male or female patients older than 18 years
Patients with confirmed HCC with or without PVTT (Diagnosed by two imaging modalities or one imaging modality with elevated serum alpha fetoprotein or liver biopsy)

Exclusion Criteria

Prior locoregional therapy or liver transplantation
Patients on vitamin K, vitamin K antagonists or antibiotics
Patients with cholestasis
Patients with renal insufficiency
Patients with other malignancies
Unwilling to participate in our study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.56
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.57
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.58
Sign up59

Send a message24

Enter your contact details to connect with study team25

Investigator Avatar

Primary Contact26

First name*27
Last name*30
Email*33
Phone number*37
Preferred way of contact label
Race
Ethnicity
Other language43

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.